Could a common heart drug spark new muscle growth in babies with heart defects?
NCT ID NCT04713657
First seen Nov 18, 2025 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This early-stage trial tests whether the beta-blocker propranolol can stimulate heart muscle cell growth in infants born with Tetralogy of Fallot, a serious heart defect. Forty infants under 60 days old will receive propranolol, and researchers will measure new heart muscle cells in tissue discarded during surgery. The goal is to see if this approach could eventually prevent heart failure later in life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETRALOGY OF FALLOT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Upmc Children'S Hospital of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact
Contact Email: •••••@•••••
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Propranolol (a beta-blocker medicine)
What this could lead to
If it works, this could point toward a treatment that helps infants with congenital heart disease grow new heart muscle cells, potentially reducing their risk of heart failure later in life.
What could go wrong
This is a very early Phase 1 trial with only 40 infants, so it is not yet known if propranolol is effective or safe for this purpose. The study is small and exploratory, so results may not lead to a proven therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.